High drug prices are a national crisis. Policymakers in three different states (Washington, Maine, and Hawaii) have introduced price control legislation. Of note was the emphasis placed on independently run ICER’s reports and recommendations. ICER has been markedly critical of unjustified price increases.
ICER’s Chief Operating Officer Sarah Emond remarks, “They wanted to be able to judge what they were finding in their price transparency work and they wanted something that was technically easy to implement. Having that freely available report from ICER each year helps them achieve that ‘technically easy’ piece… [ICER’s nonpartisan independence] is why states are considering using our freely available research to help them achieve better value for their prescription drug spending.” Read more here.
(Source: Gabrielle Wanneh, Inside Health Policy, 2/19/21)